NASDAQ:AERI - Aerie Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $23.08
Forecasted Upside: 48.82 %
Number of Analysts: 7
Breakdown:
1 Sell Ratings
1 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$15.51 As of 07/23/2021 01:00 AM ET

▼ -0.02 (-0.13%)

1 month | 3 months | 12 months

Get New Aerie Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for AERI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AERI

^$23.08

▲ +48.82% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for Aerie Pharmaceuticals in the last 3 months. The average price target is $23.08, with a high forecast of $32.00 and a low forecast of $9.00. The average price target represents a 48.82% upside from the last price of $15.51.

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Aerie Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
11 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

2/1/2020

0 strong buy ratings
11 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

5/1/2020

0 strong buy ratings
11 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

7/30/2020

0 strong buy ratings
11 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

10/28/2020

0 strong buy ratings
9 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

1/26/2021

0 strong buy ratings
8 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

4/26/2021

0 strong buy ratings
5 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

6/25/2021

0 strong buy ratings
5 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

7/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
7/23/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	N/A
7/22/2021	Mizuho	Reiterated Rating	Buy	$28.00	High
7/16/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Medium
7/13/2021	Raymond James	Set Price Target		$15.65	Low
7/12/2021	Raymond James	Reiterated Rating	Hold		Low
7/9/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Low
7/2/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Low
4/30/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Medium
4/23/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Medium
3/1/2021	HC Wainwright	Reiterated Rating	Buy		High
2/5/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Low
12/28/2020	Mizuho	Reiterated Rating	Buy	$28.00	N/A
12/28/2020	Needham & Company LLC	Reiterated Rating	Buy	$26.00	N/A
11/9/2020	HC Wainwright	Lower Price Target	Buy	$31.00 ➝ $29.00	High
11/6/2020	Mizuho	Reiterated Rating	Buy		High
10/19/2020	Bank of America	Downgrade	Neutral ➝ Underperform	$14.00 ➝ $9.00	High
10/5/2020	Raymond James	Reiterated Rating	Hold		High
10/5/2020	Needham & Company LLC	Reiterated Rating	Buy	$26.00	Medium
9/28/2020	Raymond James	Reiterated Rating	Hold		Medium
9/8/2020	Raymond James	Reiterated Rating	Hold		Medium
9/8/2020	Guggenheim	Initiated Coverage	Buy	$20.00	Medium
8/24/2020	Raymond James	Reiterated Rating	Hold		Medium
8/14/2020	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Low
8/10/2020	Citigroup	Lower Price Target	Buy	$38.00 ➝ $32.00	Low
8/7/2020	Piper Sandler	Lower Price Target		$35.00 ➝ $25.00	Low
8/7/2020	Mizuho	Boost Price Target	Buy	$27.00 ➝ $29.00	High
8/7/2020	Needham & Company LLC	Lower Price Target	Buy	$32.00 ➝ $26.00	High
7/28/2020	Mizuho	Reiterated Rating	Buy	$29.00	Low
7/24/2020	Needham & Company LLC	Initiated Coverage	Buy	$32.00	Medium
7/6/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	High
6/26/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	Low
6/19/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	Medium
6/12/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	Low
6/5/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	High
5/29/2020	Oppenheimer	Initiated Coverage	Buy	$22.00 ➝ $24.00	High
5/29/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	High
5/22/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	N/A
5/7/2020	SunTrust Banks	Lower Price Target	Buy	$26.00 ➝ $22.00	Medium
5/7/2020	Needham & Company LLC	Reiterated Rating	Buy		High
5/7/2020	Mizuho	Lower Price Target	Buy	$34.00 ➝ $29.00	High
5/7/2020	Piper Sandler	Lower Price Target	Overweight	$45.00 ➝ $35.00	High
5/7/2020	HC Wainwright	Lower Price Target	Buy	$37.00 ➝ $31.00	High
4/30/2020	Needham & Company LLC	Lower Price Target	Buy	$40.00 ➝ $38.00	Low
4/24/2020	Needham & Company LLC	Reiterated Rating	Buy	$40.00	Medium
4/13/2020	Mizuho	Lower Price Target	Buy	$54.00 ➝ $34.00	Medium
4/13/2020	Oppenheimer	Lower Price Target	Outperform	$28.00 ➝ $26.00	Low
4/13/2020	Needham & Company LLC	Reiterated Rating	Buy	$40.00	Low
4/1/2020	Stifel Nicolaus	Lower Price Target	Buy	$45.00 ➝ $40.00	Medium
3/27/2020	Needham & Company LLC	Reiterated Rating	Buy	$40.00	High
3/23/2020	Bank of America	Lower Price Target	Neutral	$26.00 ➝ $17.00	Low
3/23/2020	Bank of America	Reiterated Rating	Hold	$17.00	Low
2/28/2020	Mizuho	Reiterated Rating	Buy		Medium
2/21/2020	HC Wainwright	Lower Price Target	Buy	$41.00 ➝ $37.00	High
2/21/2020	JMP Securities	Reiterated Rating	Outperform ➝ Average	$35.00	High
2/16/2020	Needham & Company LLC	Reiterated Rating	Buy	$40.00	High
2/13/2020	Piper Sandler	Lower Price Target		$48.00 ➝ $45.00	Low
1/10/2020	Bank of America	Initiated Coverage	Neutral	$27.00	High
1/9/2020	SunTrust Banks	Initiated Coverage	Buy	$32.00	High
12/30/2019	Needham & Company LLC	Reiterated Rating	Buy	$40.00	High
12/20/2019	Mizuho	Reiterated Rating	Buy	$54.00	High
12/19/2019	Citigroup	Initiated Coverage	Buy	$36.00	High
12/6/2019	Needham & Company LLC	Initiated Coverage	Buy	$40.00	Low
12/5/2019	Mizuho	Reiterated Rating	Buy	$54.00	High
11/29/2019	Needham & Company LLC	Reiterated Rating	Buy	$40.00	Low
11/18/2019	Needham & Company LLC	Reiterated Rating	Buy	$40.00	Low
11/7/2019	Oppenheimer	Lower Price Target		$45.00 ➝ $25.00	High
11/7/2019	JMP Securities	Lower Price Target	Outperform	$41.00	High
11/7/2019	Stifel Nicolaus	Lower Price Target	Buy	$77.00 ➝ $45.00	High
11/7/2019	Cowen	Reiterated Rating	Outperform	$105.00 ➝ $50.00	High
11/7/2019	HC Wainwright	Lower Price Target	Buy	$55.00 ➝ $41.00	High
11/7/2019	Cantor Fitzgerald	Lower Price Target	Overweight	$62.00 ➝ $30.00	High
11/7/2019	Mizuho	Reiterated Rating	Buy	$63.00 ➝ $54.00	High
10/25/2019	Needham & Company LLC	Reiterated Rating	Buy	$54.00	Low
10/24/2019	HC Wainwright	Reiterated Rating	Buy		High
10/18/2019	Mizuho	Set Price Target	Buy	$63.00	High
10/18/2019	Needham & Company LLC	Set Price Target	Buy	$54.00	High
10/15/2019	Piper Jaffray Companies	Reiterated Rating	Buy		Low
10/11/2019	Mizuho	Set Price Target	Buy	$63.00	Low
10/11/2019	Needham & Company LLC	Set Price Target	Buy	$54.00	Low
10/4/2019	Needham & Company LLC	Reiterated Rating	Buy	$54.00	Low
9/27/2019	Needham & Company LLC	Set Price Target	Buy	$54.00	Low
9/27/2019	Mizuho	Set Price Target	Buy	$63.00	Low
9/13/2019	Mizuho	Set Price Target	Buy	$63.00	High
8/16/2019	Mizuho	Set Price Target	Buy	$63.00	High
8/8/2019	HC Wainwright	Reiterated Rating	Buy	$57.00	High
8/8/2019	Citigroup	Reiterated Rating	Outperform	$65.00 ➝ $45.00	High
8/8/2019	JMP Securities	Lower Price Target	Market Outperform	$58.00 ➝ $52.00	High
8/8/2019	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$74.00 ➝ $54.00	High
8/8/2019	Piper Jaffray Companies	Lower Price Target	Overweight	$76.00 ➝ $53.00	High
8/8/2019	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$85.00 ➝ $62.00	High
8/2/2019	Mizuho	Set Price Target	Buy	$77.00	Medium
7/24/2019	HC Wainwright	Reiterated Rating	Buy	$57.00	High
7/19/2019	Mizuho	Set Price Target	Buy	$77.00	N/A
7/10/2019	Needham & Company LLC	Reiterated Rating	Buy ➝ Positive	$74.00	Low
7/5/2019	Piper Jaffray Companies	Set Price Target	Buy	$76.00	Low
7/2/2019	JMP Securities	Set Price Target	Average ➝ Outperform	$75.00 ➝ $58.00	High
6/11/2019	Canaccord Genuity	Set Price Target	Buy	$56.00	High
5/10/2019	Canaccord Genuity	Lower Price Target	Buy	$65.00 ➝ $56.00	Low
5/8/2019	Piper Jaffray Companies	Set Price Target	Buy	$76.00	High
4/21/2019	Mizuho	Reiterated Rating	Buy	$77.00	Medium
3/21/2019	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight	$80.00 ➝ $80.00	High
3/19/2019	Oppenheimer	Reiterated Rating	Buy		Low
3/19/2019	Canaccord Genuity	Set Price Target	Buy	$73.00 ➝ $65.00	Medium
3/13/2019	Mizuho	Reiterated Rating	Buy	$77.00	High
3/5/2019	Canaccord Genuity	Lower Price Target	Buy	$86.00 ➝ $73.00	Low
2/27/2019	Cowen	Reiterated Rating	Buy		Low
2/26/2019	HC Wainwright	Reiterated Rating	Buy		Medium
2/26/2019	Cantor Fitzgerald	Set Price Target	Buy	$85.00	Low
2/26/2019	Oppenheimer	Set Price Target	Buy	$64.00	Low
2/8/2019	Mizuho	Reiterated Rating	Buy		High
1/18/2019	Mizuho	Reiterated Rating	Buy	$77.00	High
12/20/2018	Canaccord Genuity	Set Price Target	Buy	$65.00	Low
12/3/2018	Oppenheimer	Initiated Coverage	Buy	$64.00	Medium
11/27/2018	Mizuho	Reiterated Rating	Buy	$77.00	High
11/12/2018	FIX	Initiated Coverage	Outperform ➝ Reduce	$64.00	Medium
11/12/2018	Oppenheimer	Initiated Coverage	Buy	$64.00	Medium
11/7/2018	Mizuho	Reiterated Rating	Buy	$77.00	High
11/6/2018	Cowen	Set Price Target	Buy	$105.00	High
10/10/2018	JMP Securities	Set Price Target	Buy	$80.00	High
10/2/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$86.00	High
9/11/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$80.00 ➝ $87.00	Medium
8/10/2018	Canaccord Genuity	Reiterated Rating	Buy	$86.00	Low
8/9/2018	Cowen	Boost Price Target	Buy	$100.00 ➝ $105.00	Low
8/9/2018	HC Wainwright	Set Price Target	Buy	$78.00	Medium
7/13/2018	Needham & Company LLC	Set Price Target	Buy	$76.00 ➝ $86.00	Low
6/5/2018	Canaccord Genuity	Set Price Target	Buy	$86.00	High
6/1/2018	Mizuho	Reiterated Rating	Buy	$77.00	High
5/15/2018	Canaccord Genuity	Set Price Target	Buy	$86.00	Low
5/9/2018	HC Wainwright	Set Price Target	Buy	$78.00	Low
5/9/2018	Mizuho	Reiterated Rating	Buy	$77.00	Low
5/8/2018	Canaccord Genuity	Set Price Target	Buy	$86.00	Low
5/8/2018	Cantor Fitzgerald	Set Price Target	Buy	$86.00	Low
5/1/2018	Mizuho	Lower Price Target	Buy	$77.00	Medium
3/29/2018	Mizuho	Set Price Target	Buy	$87.00	Low
3/5/2018	Seaport Global Securities	Reiterated Rating	Buy		Medium
3/1/2018	HC Wainwright	Set Price Target	Buy	$78.00	High
2/28/2018	Cantor Fitzgerald	Set Price Target	Buy	$86.00	High
2/16/2018	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$78.00	Medium
1/29/2018	Mizuho	Reiterated Rating	Buy	$87.00	Low
1/26/2018	Seaport Global Securities	Initiated Coverage	Buy ➝ Buy	$78.00	Low
1/25/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $86.00	Medium
12/19/2017	Mizuho	Reiterated Rating	Buy	$87.00	Low
12/18/2017	Canaccord Genuity	Set Price Target	Buy	$73.00	High
12/18/2017	Cantor Fitzgerald	Set Price Target	Buy	$77.00	High
11/16/2017	Canaccord Genuity	Set Price Target	Buy	$73.00	N/A
11/16/2017	Cantor Fitzgerald	Set Price Target	Buy	$69.00	N/A
11/9/2017	Mizuho	Reiterated Rating	Buy	$87.00	N/A
11/3/2017	Mizuho	Reiterated Rating	Buy		N/A
10/25/2017	Mizuho	Reiterated Rating	Buy	$70.00	N/A
10/23/2017	Guggenheim	Initiated Coverage	Buy	$80.00	N/A
10/16/2017	Canaccord Genuity	Reiterated Rating	Buy ➝ Positive	$65.00 ➝ $73.00	N/A
10/16/2017	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $76.00	N/A
10/16/2017	Mizuho	Reiterated Rating	Buy	$70.00	N/A
10/11/2017	JMP Securities	Set Price Target	Buy	$68.00	N/A
10/11/2017	Canaccord Genuity	Set Price Target	Buy	$65.00	N/A
10/11/2017	Cantor Fitzgerald	Reiterated Rating	Positive ➝ Buy	$62.00	N/A
10/5/2017	Cowen	Reiterated Rating	Buy		N/A
10/2/2017	Mizuho	Reiterated Rating	Buy	$70.00	High
9/22/2017	Canaccord Genuity	Reiterated Rating	Buy		Low
9/20/2017	Mizuho	Reiterated Rating	Buy	$70.00	High
9/17/2017	Needham & Company LLC	Reiterated Rating	Buy	$65.00	High
9/6/2017	Mizuho	Initiated Coverage	Buy	$70.00	Medium
8/16/2017	Canaccord Genuity	Set Price Target	Buy	$65.00	High
8/8/2017	Canaccord Genuity	Set Price Target	Buy	$65.00	Low
8/2/2017	HC Wainwright	Set Price Target	Buy	$69.00	High
8/1/2017	Canaccord Genuity	Set Price Target	Buy	$65.00	High
7/28/2017	Stifel Nicolaus	Reiterated Rating	Buy	$70.00	Medium
7/20/2017	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$56.00 ➝ $62.00	High
7/4/2017	Stifel Nicolaus	Boost Price Target	Buy	$55.00 ➝ $65.00	Medium
7/3/2017	Canaccord Genuity	Reiterated Rating	Buy	$65.00	Medium
5/26/2017	Stifel Nicolaus	Reiterated Rating	Buy		N/A
5/26/2017	Cowen	Set Price Target	Buy	$100.00	N/A
5/25/2017	Aegis	Boost Price Target	Buy	$63.00 ➝ $70.00	High
5/25/2017	HC Wainwright	Reiterated Rating	Buy	$69.00	High
5/25/2017	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$58.00 ➝ $65.00	High
5/24/2017	Cantor Fitzgerald	Set Price Target	Buy	$56.00	High
5/22/2017	Canaccord Genuity	Set Price Target	Buy	$56.00	Low
5/3/2017	HC Wainwright	Reiterated Rating	Buy	$69.00	High
4/24/2017	Needham & Company LLC	Reiterated Rating	Buy	$58.00	Low
4/18/2017	Canaccord Genuity	Reiterated Rating	Buy	$56.00	Medium
4/18/2017	Cowen	Reiterated Rating	Outperform	$70.00	Medium
4/18/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$56.00	Medium
4/18/2017	Stifel Nicolaus	Reiterated Rating	Buy	$65.00	Low
4/15/2017	HC Wainwright	Set Price Target	Buy	$69.00	Low
4/13/2017	Aegis	Reiterated Rating	Buy	$63.00	High
4/12/2017	Cantor Fitzgerald	Set Price Target	Buy	$56.00	Medium
4/6/2017	Stifel Nicolaus	Boost Price Target	Buy	$55.00 ➝ $65.00	Medium
3/31/2017	JMP Securities	Reiterated Rating	Outperform	$57.00	Low
3/11/2017	Canaccord Genuity	Set Price Target	Buy	$56.00	Low
3/9/2017	Raymond James	Downgrade	Strong-Buy ➝ Market Perform	$48.00	Low
3/8/2017	Aegis	Reiterated Rating	Buy ➝ In-Line	$63.00	High
3/8/2017	Royal Bank of Canada	Boost Price Target	Outperform	$54.00 ➝ $55.00	Medium
3/8/2017	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $58.00	Medium
3/8/2017	Cantor Fitzgerald	Boost Price Target	Overweight	$50.00 ➝ $56.00	Medium
3/8/2017	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$54.00 ➝ $55.00	Medium
3/1/2017	Canaccord Genuity	Set Price Target	Buy	$50.00	N/A
2/24/2017	Cowen	Initiated Coverage	Outperform	$70.00	N/A
2/17/2017	Roth Capital	Initiated Coverage	Buy	$69.00	N/A
12/28/2016	Needham & Company LLC	Reiterated Rating	Buy	$52.00	N/A
12/23/2016	JMP Securities	Reiterated Rating	Outperform	$49.00	N/A
12/20/2016	Canaccord Genuity	Reiterated Rating	Buy	$50.00	N/A
11/10/2016	Aegis	Reiterated Rating	Buy	$63.00	N/A
11/1/2016	Aegis	Initiated Coverage	Buy	$63.00	N/A
10/28/2016	Royal Bank of Canada	Boost Price Target	Outperform	$48.00 ➝ $49.00	N/A
10/21/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$55.00	N/A
10/8/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$50.00	N/A
10/6/2016	Stifel Nicolaus	Boost Price Target	Buy	$50.00 ➝ $55.00	N/A
10/6/2016	Brean Capital	Reiterated Rating	Buy	$48.00 ➝ $63.00	N/A
9/29/2016	Brean Capital	Set Price Target	Buy	$48.00	N/A
9/20/2016	HC Wainwright	Initiated Coverage	Buy	$66.00	N/A
9/16/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$51.00 ➝ $55.00	N/A
9/15/2016	Brean Capital	Set Price Target	Buy	$48.00	N/A
9/15/2016	Stifel Nicolaus	Boost Price Target	Buy	$40.00 ➝ $50.00	N/A
9/15/2016	Needham & Company LLC	Reiterated Rating	Buy	$45.00 ➝ $52.00	N/A
9/15/2016	Cantor Fitzgerald	Boost Price Target	Buy	$44.00 ➝ $50.00	N/A
9/15/2016	Royal Bank of Canada	Boost Price Target	Outperform	$51.00 ➝ $55.00	N/A
9/14/2016	Canaccord Genuity	Set Price Target	Buy	$44.00 ➝ $50.00	N/A
9/13/2016	Raymond James	Initiated Coverage	Outperform	$48.00	N/A
9/7/2016	Brean Capital	Reiterated Rating	Buy	$48.00	N/A
8/23/2016	Needham & Company LLC	Reiterated Rating	Buy	$45.00	N/A

(Data available from 7/25/2016 forward)

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Today's Range

Now: $15.51

$15.28

$15.85

50 Day Range

MA: $16.30

$15.16

$18.84

52 Week Range

Now: $15.51

$9.01

$21.30

Volume

233,515 shs

Average Volume

450,143 shs

Market Capitalization

$727.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Aerie Pharmaceuticals?

The following Wall Street analysts have issued research reports on Aerie Pharmaceuticals in the last twelve months: Bank of America Co., Citigroup Inc., Guggenheim, HC Wainwright, Mizuho, Needham & Company LLC, Piper Sandler, Raymond James, and Zacks Investment Research.
View the latest analyst ratings for AERI.

What is the current price target for Aerie Pharmaceuticals?

8 Wall Street analysts have set twelve-month price targets for Aerie Pharmaceuticals in the last year. Their average twelve-month price target is $23.08, suggesting a possible upside of 48.8%. Citigroup Inc. has the highest price target set, predicting AERI will reach $32.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $9.00 for Aerie Pharmaceuticals in the next year.
View the latest price targets for AERI.

What is the current consensus analyst rating for Aerie Pharmaceuticals?

Aerie Pharmaceuticals currently has 1 sell rating, 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AERI will outperform the market and that investors should add to their positions of Aerie Pharmaceuticals.
View the latest ratings for AERI.

What other companies compete with Aerie Pharmaceuticals?

Other companies that are similar to Aerie Pharmaceuticals include Editas Medicine, NanoString Technologies, Kymera Therapeutics, Alector, Instil Bio, Bavarian Nordic A/S, Sorrento Therapeutics, Vericel, Translate Bio, Revolution Medicines, Rubius Therapeutics, Cortexyme, C4 Therapeutics, bluebird bio and Century Therapeutics.

How do I contact Aerie Pharmaceuticals' investor relations team?

Aerie Pharmaceuticals' physical mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company's listed phone number is 919-237-5300 and its investor relations email address is [email protected] The official website for Aerie Pharmaceuticals is www.aeriepharma.com.